Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Arch Pharm (Weinheim) ; 357(3): e2300537, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-38096806

RESUMEN

The study aimed to analyze the effects of Dendrobium polysaccharides on the cough and airway reactivity and compare them with the effects of clinically used antitussives (codeine phosphate and butamirate citrate) and bronchodilators (salbutamol), using the guinea pig test system. Dendrobium officinale polysaccharides contained proteins (4.0 wt%) and phenolic compounds (1.7 wt%) with a molecular weight of 25,000 g/mol. The sugar analysis revealed a dominance of glucose (93.7 wt%) and a lesser amount of mannose (5.1 wt%) while other sugar quantities were negligible. Methylation analysis indicated the presence of highly branched polysaccharides. Glucose was found mainly as terminal, 1,4- and 1,6-linked. Furthermore, some 1,4- and 1,6-linked glucose units were found branched at O2, O3, and O6/O4. Mannose was terminal and 1,4-linked. NMR spectra signals indicate the presence of the (1→4)-linked α-d-glucan, (1→4)-linked ß-d-glucan branched at position O6, (1→6)-linked ß-d-glucan branched at position O3 and (1→4)-linked glucomannan. Pharmacological studies showed statistically significant antitussive activity of Dendrobium polysaccharides, exceeding the effect of clinically used antitussives, which may be partially associated with confirmed bronchodilation and the ability of polysaccharides to increase the threshold of cough receptor activation. Dendrobium polysaccharides may increase the possibility of symptomatic treatment of cough, especially in asthmatics.


Asunto(s)
Antitusígenos , Dendrobium , Animales , Cobayas , Manosa/química , Dendrobium/química , Extractos Vegetales/farmacología , Extractos Vegetales/química , Antitusígenos/farmacología , Relación Estructura-Actividad , Polisacáridos/farmacología , Polisacáridos/química , Glucosa/química , Tos , Glucanos
2.
Adv Exp Med Biol ; 1374: 63-72, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35038147

RESUMEN

Symptoms of renal cell carcinoma (RCC) have typically late onset and correlate with its advanced stage. No biomarkers of RCC are currently available. The present study analyzed the immuno-biochemical profile of RCC by measuring the levels of cytokines engaged in RCC pathophysiology. Cytokines were examined by capture sandwich immunoassays in tumor tissue and urine. Specimens of cancer and nearby healthy kidney tissues were obtained during nephrectomy from 60 RCC patients. The urine was obtained from both patients and healthy subjects. The findings in RCC tumor tissue compared to healthy renal tissues were following: (i) increases in interleukin-15 (IL-15), vascular endothelial growth factor (VEGF), interferon gamma-induced protein-10 (IP-10), macrophage inflammatory protein-1ß (MIP-1ß), monocyte chemoattractant protein-1 (MCP-1), and eotaxin, with VEGF, IP-10, and MIP-1ß significantly associated with the histologic tumor nuclear grading (NG); (ii) increases in platelet-derived growth factor (PDGF), IL-15, MIP-1ß, eotaxin, and MCP-1 in urine, with significant associations noticed between cytokines and disease stages for eotaxin and MCP-1; and (iii) decreases in PDGF, IL-15, MCP-1, VEGF, MIP-1ß, and eotaxin in urine from six patients on the third day after nephrectomy. We conclude that cytokines may play a critical role in the local pathogenesis of RCC, which opens the way for potential targeting of these molecules in novel therapies and their use as biomarkers for early noninvasive detection of RCC.


Asunto(s)
Carcinoma de Células Renales , Citocinas , Neoplasias Renales , Carcinoma de Células Renales/diagnóstico , Carcinoma de Células Renales/cirugía , Estudios de Casos y Controles , Citocinas/metabolismo , Detección Precoz del Cáncer , Humanos , Neoplasias Renales/diagnóstico , Neoplasias Renales/patología , Neoplasias Renales/cirugía
3.
J Ethnopharmacol ; 284: 114754, 2022 Feb 10.
Artículo en Inglés | MEDLINE | ID: mdl-34662663

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: Erigeron canadensis has been used in traditional medicine to treat a variety of respiratory diseases, including acute upper and lower respiratory tract infections and cough-related asthma. There is as yet no relevant experimental or clinical study in the scientific literature evaluating the efficacy of plants in these disorders. AIM OF THE STUDY: To investigate the active ingredients in Erigeron canadensis, a complex isolated from flowering parts of a plant was tested for airway defense reflexes, in particular for cough reflexes and airway reactivity. Both were experimentally induced by a chemical irritant that simulated the inflammatory conditions of their formation. MATERIAL AND METHODS: The polyphenolic polysaccharide-protein (PPP) complex was isolated from the flowering parts of Erigeron canadensis by hot alkaline extraction and a multi-stage purification process. The antitussive activity was confirmed as a decrease in the number of citric acid-induced coughs and the bronchodilator effect was verified as a decrease in specific airway resistance (sRaw) in conscious guinea pigs. RESULTS: The dark brown Erigeron complex with a molecular weight of 38,000 g/mol contained phenolics (13.2% wt%), proteins (16.3% wt%), and uronic acids (6.3% wt%). The neutral carbohydrate part of Erigeron consisted mainly of xylose (12.1 wt%), glucose (13.3 wt%), arabinose (24.1 wt%), and galactose (41.0 wt%) residues. Arabinogalactan and 4-OMe-glucuronoxylan have been found to be the major polysaccharides in the Erigeron complex. Using a method of chemically-induced cough reflex and guinea pigs test system the Erigeron complex exhibited statistically significant, the dose-dependent antitussive activity, which was similar to that of the centrally-acting opioid agonist codeine. CONCLUSION: Pharmacological tests have revealed a new pharmacodynamic effect of the Erigeron complex, namely an antitussive effect. Its activity was most pronounced in comparison with all previously tested compounds from other medicinal plants and approached the effect of codeine, the most potent antitussive used in clinical practice. The results provide the scientific basis for the application of this herb in traditional medicine.


Asunto(s)
Erigeron/química , Polifenoles/farmacología , Polisacáridos/farmacología , Proteínas/farmacología , Animales , Antitusígenos/química , Antitusígenos/aislamiento & purificación , Antitusígenos/farmacología , Codeína/farmacología , Tos/tratamiento farmacológico , Relación Dosis-Respuesta a Droga , Cobayas , Masculino , Polifenoles/química , Polifenoles/aislamiento & purificación , Polisacáridos/administración & dosificación , Polisacáridos/química , Polisacáridos/aislamiento & purificación , Proteínas/química , Proteínas/aislamiento & purificación
4.
Membranes (Basel) ; 11(7)2021 Jul 07.
Artículo en Inglés | MEDLINE | ID: mdl-34357161

RESUMEN

BACKGROUND: The presented study evaluated the suppositional changes in the airway expression of Nav1.8 and Nav1.7 and their role in the airway defense mechanisms in healthy animals and in an experimental asthma model. METHODS: The effects of the blockers inhalation on the reactivity of guinea pig airways, number of citric-acid-induced coughs and ciliary beating frequency (CBF) were tested in vivo. Chronic inflammation simulating asthma was induced by repetitive exposure to ovalbumin. The expression of Nav1.7 and Nav1.8 was examined by ELISA. RESULTS: The Nav 1.8 blocker showed complex antitussive and bronchodilatory effects and significantly regulated the CBF in healthy and sensitized animals. The Nav1.7 blockers significantly inhibited coughing and participated in CBF control in the ovalbumin-sensitized animals. The increased expression of the respective ion channels in the sensitized animals corresponded to changes in CBF regulation. The therapeutic potency of the Nav1.8 blocker was evidenced in combinations with classic bronchodilators. CONCLUSION: The allergic-inflammation-upregulated expression of Nav1.7 and Nav1.8 and corresponding effects of blocker inhalation on airway defense mechanisms, along with the Nav1.8 blocker's compatibility with classic antiasthmatic drugs, bring novel possibilities for the treatment of various respiratory diseases. However, the influence of the Nav1.8 blocker on CBF requires further investigation.

5.
Adv Exp Med Biol ; 1335: 87-101, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33742420

RESUMEN

Airway remodeling (AR) consists of wall thickening and hyperreactivity. STIM (stromal interaction molecule) and Orai protein pathways mediate extracellular Ca2+ signals involved in AR. This study aims to define the effects on AR of the STIM-Orai antagonist SKF 96365 given by inhalation in three increasing doses in ovalbumin-induced AR. In the control group, the antiasthmatic budesonide and salbutamol were given in the same model. The airway structure was evaluated by histological and immunohistochemistry and reactivity by specific airway resistance, contraction strength of isolated airway smooth muscles, and mucociliary clearance expressed by ciliary beating frequency. The immuno-biochemical markers of chronic inflammation were evaluated by BioPlex and ELISA assays. The AR was mediated by inflammatory cytokines and growth factors. The findings show significant anti-remodeling effects of SKF 96365, which were associated with a decrease in airway hyperreactivity. The anti-remodeling effect of SKF 96365 was mediated via the suppression of IL-4, IL-5, and IL-13 synthesis, and IL-12-INF-γ-TGF-ß pathway. The budesonide-related AR suppression had to do with a decrease in proinflammatory cytokines and an increase in the anti-inflammatory IL-10, with negligible influence on growth factors synthesis and mucous glands activity.


Asunto(s)
Remodelación de las Vías Aéreas (Respiratorias) , Imidazoles , Animales , Budesonida , Cobayas , Imidazoles/farmacología , Ovalbúmina
6.
World Neurosurg ; 121: e554-e565, 2019 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30278292

RESUMEN

OBJECTIVE: In lumbar degenerative spondylolisthesis (DSL), the criteria and extent of surgical treatment have not been strictly defined owing to the adjacent segment disease theory and unclear molecular pathogenesis. The present study analyzed the clinical and radiographic findings of patients after lower lumbar fusion surgery with single and 2-level DSL and explored the inflammatory mediator's role in DSL evolution and symptoms. METHODS: The prospective follow-up of patients with DSL, stratified by the stabilization extent (L4-L5, L5-S1, and L4-S1), included the Back Illness Pain and Disability 9-item questionnaire and native and dynamic radiographs to evaluate the intervertebral disc height and adjacent segments' angular motion. Follow-up examinations were performed at 3, 12, and 24 months. The pathological cytokine concentrations in the intervertebral disc and facet joints of the subchondral bone were assessed using the BioPlex assay in perioperatively collected patient samples and compared with those of control subjects obtained during multiorgan procurement. These findings were correlated with pain localization and severity. RESULTS: Statistical analysis of the questionnaire data revealed significant postoperative improvement in all patients, in particular, the L4-L5 group. Also, we found radiographic evidence of angular motion reduction in both adjacent segments near the limits of statistical significance and a meaningful correlation with subjective status improvement at 24 months. BioPlex analysis revealed platelet-derived growth factor 2 B subunits, interleukin-6, interleukin-8, and tumor necrosis factor-α were elevated in spinal unit segments and the interleukin-1ß levels correlated significantly with the intensity of low backache. CONCLUSIONS: Our findings did not support the adjacent segment disease theory. However, later development of these changes could not be excluded. The cytokines, chemokines, and growth factors play a significant role in DSL pathogenesis and symptoms.


Asunto(s)
Degeneración del Disco Intervertebral/complicaciones , Degeneración del Disco Intervertebral/cirugía , Región Lumbosacra/cirugía , Fusión Vertebral/métodos , Espondilolistesis/complicaciones , Espondilolistesis/cirugía , Adulto , Anciano , Citocinas/metabolismo , Femenino , Estudios de Seguimiento , Humanos , Degeneración del Disco Intervertebral/diagnóstico por imagen , Región Lumbosacra/diagnóstico por imagen , Masculino , Persona de Mediana Edad , Radiografía , Rango del Movimiento Articular , Estadísticas no Paramétricas , Resultado del Tratamiento
8.
Gen Physiol Biophys ; 37(4): 391-398, 2018 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-29956670

RESUMEN

This study specified the role of several key calcium-operating ion channels in contraction/relaxation of human detrusor muscle as possible target for overactive bladder (OAB) treatment. Detrusor samples, obtained from 18 males (average age 61.5 ± 5.9 years), were investigated by organ tissue bath method with following agents: diltiazem for L-type voltage-gated calcium channels; 3-fluropyridine-4-carboxylic acid (FPCA) for Orai-STIM channels; SKF 96365-hydrochloride for transient receptor potential (TRP) channels, T-type channels and Orai-STIM channels; 2- aminoethoxydiphenyl borate (2-APB) for inositol-triphosphate receptors (IP3Rs) and Orai-STIM channels. Oxybutynin and mirabegron were tested under the same conditions as controls. Mirabegron, 2-APB and FPCA exhibited the best suppressive effect on carbachol-induced detrusor contractility. As expressed by area under the contractile curve (AUCC), 2-APB, FPCA and mirabegron have similar AUCC: 1.79, 1.73, 1.73. The highest AUCC was 3.64 for diltiazem+SKF, followed by 3.21 for diltiazem, 3.16 for SKF and 2.94 for oxybutynin. The lowest median amplitude and contraction variability is for 2-APB followed by mirabegron and FPCA. There were significant differences between: 2-APB/FPCA vs.: ditiazem, diltiazem+SKF and SKF. Summary of results suggested the principal role of IP3Rs, Orai-STIM coupling and large-conductance calcium-activated potassium channels in detrusor contraction and pointed on Orai-STIM channels as possible targets for OAB pharmacotherapy.


Asunto(s)
Calcio/metabolismo , Canales Iónicos/metabolismo , Contracción Muscular , Vejiga Urinaria/fisiología , Humanos , Masculino , Persona de Mediana Edad , Vejiga Urinaria/metabolismo , Vejiga Urinaria/fisiopatología , Vejiga Urinaria Hiperactiva/metabolismo , Vejiga Urinaria Hiperactiva/fisiopatología
9.
Int J Surg ; 43: 163-170, 2017 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-28600230

RESUMEN

BACKGROUND: Lumbar degenerative spondylolisthesis (DS) develops as a result of inflammatory and remodeling processes in facet joints (FJs). Several inflammatory cytokines are involved in the osteoarthritic and remodeling changes that occur and in low-back and/or radicular pain, the most prevalent clinical symptom of disease. This study improves knowledge related to the roles that 27 cytokines, chemokines and growth factors play in the pathophysiology of lumbar DS. MATERIAL AND METHODS: Cytokine levels were examined using capture sandwich immunoassay using the Bio-Plex® 200 System and the Bio-PlexTM Human Cytokine Standard 27-Plex, Group I (Bio-Rad, Hercules, California, USA) separately in intervertebral discs (IVDs) and FJ bone tissue. The samples were obtained during primary spinal surgery from 9 patients suffering from lower segment lumbar DS. The pain intensity was assessed using a visual analog scale. The controls were tissue samples collected from both lower lumbar segment levels of 6 male subjects during a multiorgan procurement procedure. RESULTS: The Bio-Plex® assay revealed significant differences between the patients and controls in cytokines, chemokines and growth factor profiles: i, The elevated interleukin-6 (IL-6), IL-7, IL-13, tumor necrosis factor α (TNF-α), interferon γ and platelet-derived growth factor levels in lumbar DS samples of subchondral FJ bone. These indicated ongoing inflammation, bone formation and increased fibroblasts activity in the FJ bone. ii, The elevated levels of IL-6, IL-8, TNF-α, granulocyte-macrophage colony-stimulating factor and monocyte chemoattractant protein-1 in anulus fibrosus together with increased IL-6, IL-8, TNF-α and eotaxin and decreased IL-1-receptor antagonist in nucleus pulposus confirmed advanced IVD degeneration in the patient samples. CONCLUSION: This study identified, for the first time, protective levels of cytokines, chemokines and growth factors in healthy subjects and supported their significant involvement in the pathogenesis of lumbar DS. The control samples and analytical methods used avoided any false changes in the cytokine levels due to secondary factors (e.g., death of donor and limited cytokine stability).


Asunto(s)
Quimiocinas/fisiología , Citocinas/fisiología , Vértebras Lumbares , Espondilolistesis/inmunología , Adulto , Anciano , Quimiocinas/análisis , Citocinas/análisis , Femenino , Humanos , Degeneración del Disco Intervertebral/complicaciones , Masculino , Persona de Mediana Edad , Núcleo Pulposo/inmunología , Espondilolistesis/etiología
10.
Int J Biol Macromol ; 103: 863-869, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-28528945

RESUMEN

Microalgae organisms are of interest for many biotechnology applications due to the production of a wide range of biologically active compounds. Incubation of Wollea saccata in a large scale afforded a mucilaginous, high molecular weight biopolymer composed of carbohydrate, protein and phenolic compounds. Sugar moiety was rich in hexoses (60%) and 6-deoxyhexoses (31%), while only 9% of pentoses was identified. Methylation analysis revealed about 40 types of methylated sugar derivatives, suggesting a very complex structure of Wollea biopolymer. Pharmacological studies revealed new pharmacodynamic properties of cyanobacteria biopolymer, i.e. antitussive and bronchodilatory. Biopolymer was able to suppress the cough reflex induced by chemical tussigen, but its effect was lower than that of codeine, the strongest antitussive agent. The bronchodilatory effect was similar or higher than the effect of salbutamol, a bronchodilatory drug used in a clinical practice. In pharmacological studies, there were no signs of toxicity or side effects in the animals following administration of Wollea biopolymer.


Asunto(s)
Biopolímeros/química , Biopolímeros/farmacología , Cianobacterias/citología , Espacio Extracelular/química , Animales , Antitusígenos/química , Antitusígenos/farmacología , Broncodilatadores/química , Broncodilatadores/farmacología , Cobayas , Masculino
11.
J Pharmacol Exp Ther ; 361(1): 172-180, 2017 04.
Artículo en Inglés | MEDLINE | ID: mdl-28138042

RESUMEN

Little is known about the neuronal voltage-gated sodium channels (NaVs) that control neurotransmission in the parasympathetic nervous system. We evaluated the expression of the α subunits of each of the nine NaVs in human, guinea pig, and mouse airway parasympathetic ganglia. We combined this information with a pharmacological analysis of selective NaV blockers on parasympathetic contractions of isolated airway smooth muscle. As would be expected from previous studies, tetrodotoxin potently blocked the parasympathetic responses in the airways of each species. Gene expression analysis showed that that NaV 1.7 was virtually the only tetrodotoxin-sensitive NaV1 gene expressed in guinea pig and human airway parasympathetic ganglia, where mouse ganglia expressed NaV1.1, 1.3, and 1.7. Using selective pharmacological blockers supported the gene expression results, showing that blocking NaV1.7 alone can abolish the responses in guinea pig and human bronchi, but not in mouse airways. To block the responses in mouse airways requires that NaV1.7 along with NaV1.1 and/or NaV1.3 is blocked. These results may suggest novel indications for NaV1.7-blocking drugs, in which there is an overactive parasympathetic drive, such as in asthma. The data also raise the potential concern of antiparasympathetic side effects for systemic NaV1.7 blockers.


Asunto(s)
Ganglios Parasimpáticos/fisiología , Pulmón/fisiología , Canal de Sodio Activado por Voltaje NAV1.7/fisiología , Fibras Parasimpáticas Posganglionares/fisiología , Transmisión Sináptica/fisiología , Animales , Relación Dosis-Respuesta a Droga , Ganglios Parasimpáticos/efectos de los fármacos , Cobayas , Células HEK293 , Humanos , Pulmón/efectos de los fármacos , Masculino , Ratones , Músculo Liso/efectos de los fármacos , Músculo Liso/fisiología , Técnicas de Cultivo de Órganos , Fibras Parasimpáticas Posganglionares/efectos de los fármacos , Bloqueadores de los Canales de Sodio/farmacología , Transmisión Sináptica/efectos de los fármacos
12.
Eur J Pharmacol ; 772: 62-70, 2016 Feb 05.
Artículo en Inglés | MEDLINE | ID: mdl-26724844

RESUMEN

The increase in intracellular Ca(2+) levels through the activation of Ca(2+) release-activated Ca(2+) (CRAC) channels is essential for mediating a wide scale of immune cell responses. Emerging evidence indicates an involvement of abnormal CRAC channel activity in human diseases such as certain types of immunodeficiency, autoimmunity and allergic disorders. This objective of this study was to evaluate the therapeutic potency of a novel CRAC channel inhibitor, RP3128, in experimental models of allergic asthma using guinea pigs. Ovalbumin-induced allergic airway inflammation was determined upon acute and long-term (14 days) oral administration of RP3128. In vivo changes in specific airways resistance (sRaw) and amplitude of isometric contraction (mN) of ASM (in vitro) were estimated to evaluate bronchodilatory effect upon acute and long-term administration of RP3128 or salbutamol. Exhaled nitric oxide (eNO), immunohistochemical and histological analysis of cellular infiltration in airways tissue, and levels of cytokines in plasma as well as bronchoalveolar lavage fluid (BALF), were determined using Bio-Plex® 200 System (BIO-RAD, USA). Ciliary beat frequency (CBF, in Hz) was estimated using a high-speed video camera and LabVIEW™ Software. Additionally, the impact of RP3128 and budesonide on mucociliary clearance was determined. Acute and long-term administration of RP3128 resulted in significant bronchodilation. Long-term administration of RP3128 exceeded the bronchodilatory effect of salbutamol and significantly decreased eNO and cytokine levels in plasma and BALF, which together with histological and immunohistochemical analysis validated its anti-inflammatory effect compared to budesonide. Data demonstrate the therapeutic potential of RP3128 in respiratory diseases causally associated with allergic inflammation.


Asunto(s)
Amidas/farmacología , Asma/tratamiento farmacológico , Asma/metabolismo , Bloqueadores de los Canales de Calcio/farmacología , Canales de Calcio/metabolismo , Hipersensibilidad/complicaciones , Pirazoles/farmacología , Amidas/uso terapéutico , Animales , Asma/complicaciones , Asma/inmunología , Líquido del Lavado Bronquioalveolar , Bloqueadores de los Canales de Calcio/uso terapéutico , Citocinas/sangre , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Eosinófilos/efectos de los fármacos , Eosinófilos/inmunología , Cobayas , Humanos , Pulmón/efectos de los fármacos , Pulmón/inmunología , Masculino , Mastocitos/efectos de los fármacos , Mastocitos/inmunología , Óxido Nítrico/metabolismo , Pirazoles/uso terapéutico , Reflejo/efectos de los fármacos
13.
Int J Biol Macromol ; 79: 388-91, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25999016

RESUMEN

Echinacea purpurea has a long history in traditional medicine. To verify the pharmacological efficacy of active principles, a polysaccharide-phenolic-protein complex has been isolated from flowering parts of herb by alkaline extraction. It showed on GPC and HPLC one peak of molecular mass around 10 kDa. Chemical and spectroscopic analyses revealed carbohydrate, phenolic and protein contents in Echinacea complex. Pharmacological tests have shown its marked cough suppressing and bronchodilatory effects. The antitussive effect of Echinacea was similar to the narcotic drug codeine and the bronchodilatory effect was more significant than salbutamol, the antiasthmatic drug used in a clinical practice. Pharmacodynamic study shows the beneficial effects of Echinacea complex on the respiratory system and highlights the great potential for development of antitussive and bronchodilatory drugs from natural sources.


Asunto(s)
Antitusígenos/farmacología , Tos/tratamiento farmacológico , Echinacea/química , Polisacáridos/farmacología , Sistema Respiratorio/efectos de los fármacos , Albuterol/farmacología , Animales , Antitusígenos/aislamiento & purificación , Broncodilatadores/farmacología , Cromatografía Líquida de Alta Presión , Ácido Cítrico , Codeína/farmacología , Tos/inducido químicamente , Tos/fisiopatología , Flores/química , Cobayas , Masculino , Extractos Vegetales/química , Pletismografía , Polisacáridos/aislamiento & purificación , Sistema Respiratorio/fisiopatología
14.
Gen Physiol Biophys ; 34(2): 167-76, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25730896

RESUMEN

Previously, therapeutic potency of CRAC channels blocker was evidenced as a significant decrease in airway smooth muscle hyperreactivity, antitussive and anti-inflammatory effects. The major role of the respiratory epithelium in asthma pathogenesis was highlighted only recently and CRAC channels were proposed as the most significant route of Ca2+ entry into epithelial cells. The aim of the study was to analyse the impact of long-term administered CRAC channels blocker on airway epithelium, e.g. cytokine production and ciliary beat frequency (CBF) using an animal model of allergic asthma. Ovalbumin-induced allergic airway inflammation of guinea pigs was followed by long-term (14 days lasted) therapy by CRAC blocker (3-fluoropyridine-4-carboxylic acid, FPCA). The influence of long-term therapy on cytokines (IL-4, IL-5 and IL-13) in BALF and in plasma, immunohistochemical staining of pulmonary tissue (c-Fos positivity) and CBF in vitro were used for analysis. Decrease in cytokine levels and in c-Fos positivity confirmed an anti-inflammatory effect of long-term administered FPCA. Cytokine levels in BALF and distribution of c-Fos positivity suggested that FPCA was a more potent inhibitor of respiratory epithelium secretory functions than budesonide. FPCA and budesonide reduced CBF only insignificantly. All findings supported CRAC channels as promising target in the new strategy of antiasthmatic treatment.


Asunto(s)
Asma/tratamiento farmacológico , Asma/inmunología , Canales de Calcio/inmunología , Señalización del Calcio/inmunología , Citocinas/inmunología , Ácidos Isonicotínicos/administración & dosificación , Mucosa Respiratoria/inmunología , Animales , Asma/inducido químicamente , Bloqueadores de los Canales de Calcio/administración & dosificación , Señalización del Calcio/efectos de los fármacos , Cobayas , Estudios Longitudinales , Masculino , Ovalbúmina , Mucosa Respiratoria/efectos de los fármacos , Resultado del Tratamiento
15.
J Obstet Gynaecol Res ; 41(5): 704-11, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25490950

RESUMEN

AIM: This experimental in vitro study examined differences in the expression and activity of calcium release-activated calcium (CRAC) channels of human term-pregnant and non-pregnant myometrium. MATERIAL AND METHODS: The tissue samples were obtained from term-pregnant myometrium in labor of women undergoing cesarean section and from non-pregnant myometrium of women undergoing total hysterectomy due to uterine myoma. The expression of Orai1 protein, a pore-forming subunit of CRAC channels, in human myometrium was examined using immunohistochemistry. CRAC channel involvement in the amplitude and frequency of myometrial contractions was evaluated in vitro using a tissue bath method with a CRAC ion channel blocker 3-fluropyridine-4-carboxylic acid (FPCA). RESULTS: Decreased Orai1 expression was observed in human term-pregnant laboring myometrium compared with non-pregnant myometrium. However, the initial oxytocin-induced contraction of myometrium was significantly suppressed at different doses of FPCA in both non-pregnant human isolated myometrium and non-pregnant myometrium. The frequency of contractions was the most significantly reduced at the lowest dose of FPCA in non-pregnant myometrium and remained suppressed at all doses of FPCA in term-pregnant myometrium. Salbutamol was shown as more effective in suppression of amplitude in term-pregnant isolated myometrium. CONCLUSION: Our results provide the first information about the changes in the Orai1 protein expression and activity of human myometrial CRAC channels in term-pregnant laboring myometrium.


Asunto(s)
Miometrio/metabolismo , Proteína ORAI1/metabolismo , Contracción Uterina/metabolismo , Albuterol/farmacología , Bloqueadores de los Canales de Calcio/farmacología , Femenino , Humanos , Ácidos Isonicotínicos/farmacología , Miometrio/efectos de los fármacos , Proteína ORAI1/genética , Embarazo , Contracción Uterina/efectos de los fármacos , Contracción Uterina/genética
16.
Gen Physiol Biophys ; 32(2): 251-9, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23682025

RESUMEN

The best-studied store-operated Ca2+ channels (SOCs), Ca2+ release activated Ca2+ (CRAC) channels, are activated by depleting endoplasmic reticulum Ca2+ pool and mediate Ca2+ influx vitally important for Ca2+ restoration and many cellular function. CRAC channels were identified on immune and airway smooth muscle (ASM) cells. Emerging evidence points to its involvement in allergic airways diseases. This article evaluated therapeutic potency of CRAC antagonist in experimental animal model of allergic asthma. Allergic asthma, induced by repetitive exposure of guinea pigs to ovalbumine, was followed by 14 days therapy by CRAC antagonist (3-fluoropyridine-4-carboxylic acid, FPCA). In vivo changes of specific airways resistance (sRaw) evaluated bronchodilatory effect of FPCA and salbutamol. The method of citric acid-induced cough reflex assessed antitussive activity of FPCA and codeine. The measurement of exhaled NO (ENO), expression of inducible NO-synthase (iNOS) by RT-PCR and immunohistochemical staining of airways tissue verified anti-inflammatory effect of FPCA. Long-term administration of FPCA resulted in significant cough suppression and bronchodilation, both comparable to the effect of control drugs. FPCA significantly decreased ENO and iNOS expression, which together with immunohistochemical analysis validated its anti-inflammatory effect. Presented data confirmed CRAC channels as a promising target for treatment of respiratory diseases associated with allergic inflammation.


Asunto(s)
Antiinflamatorios/administración & dosificación , Antitusígenos/administración & dosificación , Asma/tratamiento farmacológico , Asma/fisiopatología , Broncodilatadores/administración & dosificación , Bloqueadores de los Canales de Calcio/administración & dosificación , Pulmón/fisiopatología , Animales , Cobayas , Estudios Longitudinales , Pulmón/efectos de los fármacos , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...